Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jiu-Hong Wang"'
Autor:
Fu-xue Huang, Jun-wan Wu, Xia-qin Cheng, Jiu-hong Wang, Xi-zhi Wen, Jing-jing Li, Qiong Zhang, Hang Jiang, Qiu-yue Ding, Xiao-feng Zhu, Xiao-shi Zhang, Ya Ding, Dan-dan Li
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundAs a recognized highly immunogenic tumor, immune checkpoint blockades (ICB) have been widely used as a systemic treatment option for melanoma. However, only about half of treated patients could benefit from it in Caucasians, and only about
Externí odkaz:
https://doaj.org/article/5291d2152a944ee893c5f2e00d358611
Autor:
Xing Liu, Jing-jing Li, Ya Ding, Dan-dan Li, Xi-zhi Wen, De-sheng Weng, Jiu-hong Wang, Hang Jiang, Xiao-shi Zhang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The toxicity spectrum between Chinese and Caucasian patients with melanoma who were treated with BRAF inhibitors (BRAFi) may differ. The purpose of the present study was to assess the safety and tolerability of BRAFi and BRAFi-based combination thera
Externí odkaz:
https://doaj.org/article/3bc39f885d4743a6bbc1282db6981dad
Autor:
Xizhi Wen, Xiaoshi Zhang, Fuxue Huang, Jiu-Hong Wang, Ya Ding, Xing Liu, Hang Jiang, Dan Dan Li, Jingjing Li
Publikováno v:
Dermatologic Therapy. 34
e21516 Background: The clinical efficacy of PD-1 inhibitors as an adjuvant treatment for Asian melanoma patients has not yet been determined. Methods: Thus, this single-centre, retrospective study analysed the clinical data of 90 Chinese patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2090335a45d3737b2b16d09f27073240
https://doi.org/10.1111/dth.15067
https://doi.org/10.1111/dth.15067
Autor:
Ya Dingv, Hang Jiang, Jiu-Hong Wang, Xiaoshi Zhang, Dan Dan Li, Jing Jing Zhao, Xizhi Wen, Jingjing Li, Xing Liu, Fuxue Huang
Publikováno v:
Journal of cancer research and clinical oncology. 148(5)
This retrospective study aimed to evaluate the combined effect of anti-PD-1 inhibitor and nanoparticle albumin-bound (nab)-paclitaxel for refractory melanoma among Chinese patients. Data from January 2018 to March 2021 were retrospectively collected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e74498f8241a85bddafb8fe0aeacfd4a
https://pubmed.ncbi.nlm.nih.gov/34181096
https://pubmed.ncbi.nlm.nih.gov/34181096
Autor:
Xiaoshi Zhang, Jingjing Li, De-Sheng Weng, Jiu-Hong Wang, Ya Ding, Xizhi Wen, Hang Jiang, Xing Liu, Dan Dan Li
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
The toxicity spectrum between Chinese and Caucasian patients with melanoma who were treated with BRAF inhibitors (BRAFi) may differ. The purpose of the present study was to assess the safety and tolerability of BRAFi and BRAFi-based combination thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14d3d010bc3df51e2cb4d52baf63fbef
https://www.frontiersin.org/articles/10.3389/fonc.2021.582676/full
https://www.frontiersin.org/articles/10.3389/fonc.2021.582676/full